COVID-19
COVID-19 is the disease caused by the SARS-CoV-2 coronavirus. It spreads through particles released into the air when an infected person breathes, speaks, sings, coughs or sneezes. Most infected people have mild to moderate illness, but some develop serious disease or die. Older adults and people with certain underlying conditions face greater risks, although severe illness can occur at any age. Vaccines help prevent severe disease and death. Early antiviral treatment is available for eligible patients, and medical assessment is important for people at higher risk. Better ventilation, properly fitted masks and staying home when unwell can help reduce spread. The virus circulates worldwide and continues to evolve. WHO ended the international emergency designation on 2023-05-05; this did not mean that the disease had disappeared. The latest WHO outbreak notice retrieved for this page is dated 2025-05-28. Its figures describe conditions in 2025, not the situation on 2026-11-22.
Key facts
| Transmission | Respiratory particles, including small airborne particles, released during breathing, speaking, singing, coughing or sneezing. |
|---|---|
| Incubation | WHO's general overview reports an average of 5–6 days, with symptoms sometimes taking up to 14 days; this is not a current variant-specific estimate. |
| Case fatality | unknown; the retrieved sources do not provide a comparable case-fatality estimate with and without treatment. |
| Reproduction number | unknown; no numerical R0 or secondary attack rate was available in the retrieved text. |
| Vaccine | Available; WHO identifies vaccination as a key intervention against severe disease and death, particularly for at-risk groups. |
| Treatment | Many mild cases need symptom care only. Early oral antiviral treatment, including nirmatrelvir/ritonavir, is available for eligible patients; serious illness requires medical care. |
| Reservoir | Humans sustain worldwide circulation. The archive also records mink-associated variants; the retrieved sources do not establish the original animal reservoir. |
| Endemic regions | Worldwide; WHO reports continuing circulation without a clear global seasonal pattern. |
Transmission
SARS-CoV-2 spreads from an infected person's mouth or nose in respiratory particles. These are released during ordinary breathing and speaking, as well as singing, coughing and sneezing. Some particles are small enough to travel through the air. A 2024 evidence review describes strong and consistent evidence for airborne transmission. WHO recommends choosing open, well-ventilated spaces rather than closed spaces and wearing a properly fitted mask in poorly ventilated settings. Staying home when unwell also helps reduce exposure to others. Hand hygiene and covering coughs are additional precautions. Human-to-human spread is already an established feature of COVID-19, not a new warning sign.
- Coronavirus WHO
- Masks and respirators for prevention of respiratory infections: a state of the science review. Europe PMC · 22 May 2024
Symptoms and severity
Common symptoms listed by WHO include fever, cough, tiredness and loss of taste or smell. Sore throat, headache, aches and diarrhoea can also occur. Most infected people recover without hospitalization, but some become seriously ill. Older people and those with cardiovascular disease, diabetes, chronic respiratory disease or cancer are more likely to develop serious illness. Severe disease can nevertheless occur at any age. Difficulty breathing, chest pain, confusion, or loss of speech or mobility require immediate medical attention. WHO's general overview gives an average incubation period—the time from infection to symptoms—of 5–6 days, sometimes up to 14 days. This is not a variant-specific estimate. The retrieved evidence does not support one fatality percentage for all patients or separate treated and untreated groups.
- Coronavirus WHO
- Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Europe PMC · 10 Apr 2023
Treatment and vaccines
Vaccines are available, and WHO describes vaccination as a key way to prevent severe COVID-19 and death, especially in at-risk groups. Follow local recommendations about eligibility and updated doses. Vaccination should not be treated as a guarantee against infection. Most otherwise healthy people with mild symptoms can manage their illness at home, according to WHO, but serious symptoms need urgent assessment. Antiviral medicines are also available for eligible patients. A 2022 review describes oral nirmatrelvir combined with ritonavir and stresses the importance of treatment early in the illness. People at higher risk should seek medical advice promptly rather than wait for symptoms to worsen. The sources retrieved here do not establish the latest country-specific treatment or vaccine recommendations for 2026.
- COVID-19 - Global Situation WHO · 28 May 2025
- Coronavirus WHO
- Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Europe PMC · 17 Nov 2022
Where it occurs
COVID-19 occurs worldwide. WHO's 2025-05-28 notice described rising activity mainly in the Eastern Mediterranean, South-East Asia and Western Pacific regions. As of 2025-05-11, 11% of specimens tested at reporting surveillance sites were positive across 73 countries, areas and territories. This measures positivity among tested specimens, not the proportion of the world's population infected. Other regions reported lower activity at that time, although some areas showed increasing trends. WHO noted that circulation still lacked clear seasonality and that surveillance was limited. These findings cannot establish where activity is highest on 2026-11-22. The archive also contains mink-associated variant notices, but those records do not establish the virus's original animal reservoir.
- COVID-19 - Global Situation WHO · 28 May 2025
- SARS-CoV-2 mink- associated variant strain – Denmark WHO Disease Outbreak News · 3 Dec 2020
- SARS-CoV-2 mink-associated variant strain WHO Disease Outbreak News · 6 Nov 2020
Recent history
Open Outbreak's archive contains nine COVID-19 events. These are archive entries, not a count of all outbreaks or infection waves. They include early notices concerning China, Thailand and Japan in January 2020, mink-associated variants and a United Kingdom variant in 2020, the pandemic record, and a global situation notice dated 2025-05-28. WHO ended the international emergency designation on 2023-05-05. In the retrieved 2025 notice, WHO reported renewed increases in virus activity and a growing share of the NB.1.8.1 variant. Its cited global assessment for July–December 2024 still rated the public-health risk as high, despite reduced health impact compared with earlier pandemic years. No later WHO outbreak notice was returned in this session; this is not evidence that no later developments occurred.
- Novel Coronavirus – China WHO Disease Outbreak News · 12 Jan 2020
- Novel Coronavirus – Thailand WHO Disease Outbreak News · 14 Jan 2020
- Novel Coronavirus – Japan WHO Disease Outbreak News · 16 Jan 2020
- SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern Ireland WHO Disease Outbreak News · 21 Dec 2020
What to watch
Important warning signals include rising hospital admissions and deaths, sustained increases in test positivity or wastewater measurements, and renewed spread in regions with previously low activity. Because human-to-human transmission is already established, the concern is a change in how easily the virus spreads or how severe illness becomes. Variant monitoring should look for reduced protection from prior infection or vaccination; research on the shift from XBB to JN.1 illustrates why vaccine composition needs reassessment. Evidence that treatments work less well would also warrant attention, although these sources do not establish a current resistance trend. Vaccine supply, access and uptake among high-risk groups matter. WHO's 2025 notice highlighted low uptake and gaps in hospitalization and death reporting, which can make worsening conditions harder to detect.
- COVID-19 - Global Situation WHO · 28 May 2025
- Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Europe PMC · 7 Nov 2024
- Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Europe PMC · 10 Apr 2023